Loading...
XOSL
CONTX
Market cap37mUSD
Oct 20, Last price  
4.55NOK
1D
-3.19%
1Q
39.14%
Jan 2017
-8.08%
Name

ContextVision AB

Chart & performance

D1W1MN
XOSL:CONTX chart
P/E
487.55
P/S
3.36
EPS
0.01
Vol. 1Y
58.60%
Shs. 5Y
-0.36%
Rev. 5Y
3.08%
Div Yld LY
—
Div Yld TTM
—
Revenues
110m
-15.61%
51,951,00069,041,00071,091,00054,731,00053,412,00058,366,00067,115,00061,277,00064,398,00072,237,00081,917,00080,512,00090,903,00095,312,00094,746,00098,098,000117,824,000132,602,000130,670,000110,277,000
Net income
760k
-96.92%
6,165,00020,311,00020,197,000-8,252,000-3,298,0003,578,000620,0004,880,0005,421,0005,338,0004,253,000-1,706,000-1,179,0007,398,00012,080,00034,884,00028,791,00032,729,00024,679,000760,270
CFO
4m
-86.97%
193,00024,554,00021,964,000-9,557,00013,180,0007,734,0008,454,0007,663,00010,373,0009,156,0009,527,0001,948,0005,119,00025,076,00022,315,0009,473,00025,889,00044,748,00032,936,0004,290,169
Dividend
Nov 02, 20230.15293 NOK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ContextVision AB (publ), a medical technology enterprise established in Stockholm, Sweden, in 1983, delivers sophisticated software solutions. The firm specializes in image analysis and artificial intelligence, supplying these advanced technologies to original equipment manufacturers (OEMs) across Asia, Europe, and the United States. Their comprehensive product suite is designed to optimize image quality across various medical imaging modalities, including two-dimensional, three-dimensional, and four-dimensional ultrasound, radiography, magnetic resonance imaging (MRI), and mammography. Key offerings include: Rivent: Provides superior image quality for a broad spectrum of ultrasound applications such as women's health, general imaging, cardiovascular, and point-of-care. VolarView: An image enhancement software specifically developed for the burgeoning handheld ultrasound market. GOPiCE: A proprietary technology enabling real-time volumetric image enhancement. Altumira/Altumira Plus: A robust platform for digital radiography. An Orthopedic Package: Tailored for specialized orthopedic imaging needs. GOPView MRI2Plus: An advanced solution for MRI image improvement. INIFY Prostate Screening: Offers digital analysis for prostate biopsies.

Key people

Independent Chairman of the Board · since 2021
Gerald Potzsch
Chief Executive Officer · since 2023
Richard Hallstroem
Chief Financial Officer · since 2023
Gunnar Laethen
Chief Technology Officer · since 2022
Katarina Flood
Chief Service Officer · since 2022
Ola Lindblad
Chief Sales and Solution Officer · since 2023
Sven Guenther-Hanssen
Director · since 2011
Martin Hedlund
Director · since 2020
Martin Ingvar
Independent Director · since 2022
IPO date
Mar 06, 1997
Employees
36
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Gamla Brogatan 26
Stockholm, AB 111 20
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT